Designed inorganic porous nanovector with controlled release and MRI features for safe administration of doxorubicin by Näkki, Simo et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.ijpharm.2018.10.074
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Näkki, S., Wang, J. T-W., Wu, J., Fan, L., Rantanen, J., Nissinen, T., ... Xu, W. (2018). Designed inorganic
porous nanovector with controlled release and MRI features for safe administration of doxorubicin.
INTERNATIONAL JOURNAL OF PHARMACEUTICS. https://doi.org/10.1016/j.ijpharm.2018.10.074
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
Accepted Manuscript
Designed inorganic porous nanovector with controlled release and MRI features
for safe administration of doxorubicin
Simo Näkki, Julie T.-W. Wang, Jianwei Wu, Li Fan, Jimi Rantanen, Tuomo
Nissinen, Mikko I. Kettunen, Matilda Backholm, Robin H.A. Ras, Khulosud T.
Al-Jamal, Vesa-Pekka Lehto, Wujun Xu
PII: S0378-5173(18)30818-4
DOI: https://doi.org/10.1016/j.ijpharm.2018.10.074
Reference: IJP 17892
To appear in: International Journal of Pharmaceutics
Received Date: 24 May 2018
Revised Date: 7 October 2018
Accepted Date: 31 October 2018
Please cite this article as: S. Näkki, J.T. Wang, J. Wu, L. Fan, J. Rantanen, T. Nissinen, M.I. Kettunen, M. Backholm,
R.H.A. Ras, K.T. Al-Jamal, V-P. Lehto, W. Xu, Designed inorganic porous nanovector with controlled release and
MRI features for safe administration of doxorubicin, International Journal of Pharmaceutics (2018), doi: https://
doi.org/10.1016/j.ijpharm.2018.10.074
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
1
1 Designed inorganic porous nanovector with controlled release 
2 and MRI features for safe administration of doxorubicin
3 Simo Näkkia,b, Julie T.-W. Wangb, Jianwei Wuc,d, Li Fanc,*, Jimi Rantanena, Tuomo Nissinena, 
4 Mikko I. Kettunene, Matilda Backholmf, Robin H.A. Rasf,g, Khulosud T. Al-Jamalb,*, Vesa-
5 Pekka Lehtoa, Wujun Xua,*
6
7 a Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, 
8 Kuopio, 70211, Finland
9 simo.nakki@uef.fi, wujun.xu@uef.fi, jimi.rantanen@uef.fi, tuomo.nissinen@uef.fi, vesa-
10 pekka.lehto@uef.fi 
11 b School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King’s 
12 College London, London SE1 9NH, UK
13 julie.tzu-wen.wang@kcl.ac.uk, khuloud.al-jamal@kcl.ac.uk
14 c Department of Pharmaceutical Analysis, School of Pharmacy, and The State Key Laboratory of 
15 Cancer Biology (CBSKL), The Fourth Military Medical University, Xi’an, Shaanxi, 710032, China.
16 113125637@qq.com, xxfanny@fmmu.edu.cn
17 d Department of Oncology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 
18 710032, China.
19 e A. I. Virtanen Institute for Molecular Science, 70221 Kuopio, Finland
20 mikko.kettunen@uef.fi
21 f Department of Applied Physics, School of Science, Aalto University, 02150 Espoo, Finland
22 matilda.backholm@aalto.fi, robin.ras@aalto.fi
23 gDepartment of Bioproducts and Biosystems, School of Chemical Engineering Aalto University, 
24 02150, Espoo, Finland
25 Corresponding Authors
26 Wujun Xu, wujun.xu@uef.fi (main correspondence), +358 403 552 348
27 Khuloud Al-Jamal, khuloud.al-jamal@kcl.ac.uk, 
28 Li Fan, xxfanny@fmmu.edu.cn.
29
30 Keywords: Porous silicon, nanoparticle, cancer therapy, biocompatibility, theranostics, 
31 safety
32
  
2
33 Abstract
34 The inability of traditional chemotherapeutics to reach cancer tissue reduces the treatment 
35 efficacy and leads to adverse effects. A multifunctional nanovector was developed consisting 
36 of porous silicon, superparamagnetic iron oxide, calcium carbonate, doxorubicin and 
37 polyethylene glycol. The particles integrate magnetic properties with the capacity to retain 
38 drug molecules inside the pore matrix at neutral pH to facilitate drug delivery to tumor 
39 tissues. The MRI applicability and pH controlled drug release were examined in vitro 
40 together with in-depth material characterization. The in vivo biodistribution and compound 
41 safety were verified using A549 lung cancer bearing mice before proceeding to therapeutic 
42 experiments using CT26 cancer implanted mice. Loading doxorubicin into the porous 
43 nanoparticle negated the adverse side effects encountered after intravenous administration 
44 highlighting the particles’ excellent biocompatibility. Furthermore, the multifunctional 
45 nanovector induced 77% tumor reduction after intratumoral injection. The anti-tumor effect 
46 was comparable with that of free doxorubicin but with significantly alleviated unwanted 
47 effects. These results demonstrate that the developed porous silicon-based nanoparticles 
48 represent promising multifunctional drug delivery vectors for cancer monitoring and therapy.
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49 1. Introduction
50 A non-specific drug distribution is a major limitation of most chemotherapeutic 
51 agents, which results in significant toxicity to healthy tissues. Doxorubicin (DOX) is a widely 
52 used chemotherapeutic drug to treat various cancers (Lu, et al. 2011); although an effective 
53 anti-cancer agent, the severe systemic toxicity of DOX in kidneys, liver and heart raises 
54 major concerns (Wu, et al. 2016). In particular, the dose-dependent cardiotoxicity and the 
55 subsequent lethal heart failure are alarming (Takemura and Fujiwara 2007). Recently, 
56 nanotechnology has made possible novel approaches and new treatment options for cancer 
57 therapy (Beik, et al. 2016; Näkki, et al. 2017; Parodi, et al. 2013). Nanoparticles have been 
58 claimed to improve the delivery of chemotherapeutics, biologics or other therapeutic 
59 molecules (Shi, et al. 2017). Loading DOX into nanoparticles has been shown to improve the 
60 safety and efficiency of the drug by delivering it specifically into the cancer tissues and 
61 protecting the drug from premature release and degradation in the blood circulation (Han, et 
62 al. 2016; Laubrock, et al. 2000; Liang, et al. 2016). Doxil® represents the first generation of 
63 nanomedicines where DOX has been loaded inside a liposome. Doxil® was approved by FDA 
64 over two decades ago for the treatment of ovarian cancer, AIDS-related Kaposi’s sarcoma 
65 and multiple myeloma; it has a prolonged blood circulation time due to its polyethylene 
66 glycol (PEG) shielding which reduces some of the unwanted effects as compared with the 
67 free drug (Barenholz 2012). However, Doxil® is still rather simple in its design and does not 
68 overcome the main problem related to liposomal drug delivery i.e. uncontrolled drug leakage 
69 (Russell, et al. 2018; Zhang, et al. 2015).
70 Nanotechnology has been explored extensively in recent decades demonstrating an 
71 impressive potential in the field of drug delivery. An optimal drug carrier should be able to 
72 overcome the body’s multiple biological barriers, e.g. the immune system, it should retain the 
73 drug molecules before their controlled release in the target and furthermore it should possess 
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74 a diagnostic potential since this would help to evaluate the efficacy of the treatment. 
75 Therefore, the current development of next generation nanomedicines has focused on 
76 combining therapeutic and diagnostic features into the same carrier (so-called ‘theranostics’) 
77 with the properties for active targeting and controlled drug release (Janib, et al. 2010; Xie, et 
78 al. 2010). In general, the trend for future nanomedicines seems to involve integrating multiple 
79 functionalities into a single carrier (Bao, et al. 2013; Cheng, et al. 2014; Cole and Holland 
80 2015; Jia, et al. 2013). Nonetheless, no matter how sophisticated the design of the 
81 nanoparticle, the safety and the therapeutic efficacy are the two most crucial factors in 
82 determining its potential exploitability. 
83 Although there is a broad selection currently being investigated, porous silicon (PSi) 
84 has proven to be a promising material. PSi has a large pore volume and thus it has a good 
85 drug molecule payload capacity as well as being biocompatible and biodegradable (Park et 
86 al., 2009, Tölli, et al. 2014). Furthermore, PSi can be easily functionalized even with multiple 
87 moieties simultaneously due to the well-known surface chemistry of silicon (Canham 1995; 
88 Näkki, et al. 2015; Salonen, et al. 2008). Previously, we have developed a tailored coating 
89 method for PSi where two PEGs (Dual PEGylation) with different molecular weights have 
90 been simultaneously incorporated to improve the in vitro and in vivo colloidal stability and 
91 behavior (Näkki, et al. 2015; Nissinen, et al. 2016). In the present paper, we report a further 
92 development of the PSi nanoparticles to make them more suitable for cancer theranostics. 
93 Our novel nanovectors are composed of a PSi core loaded with the chemotherapeutic drug, 
94 DOX, and surrounded with superparamagnetic iron oxide nanoparticles (SPIONs) with good 
95 magnetic resonance imaging (MRI) properties. Finally, the composite is coated with a pH-
96 sensitive CaCO3 layer and shielded with Dual PEGylation (Scheme 1). Nanoparticles suitable 
97 for imaging were manufactured with an identical protocol except there was no loading of 
98 DOX, instead a third PEG-molecule (Triple-PEGylation, TPEGylation) with an amine group 
  
5
99 was included to allow conjugation with a fluorescent dye (Scheme 1). Even though pH-
100 sensitive CaCO3 has been used as a drug carrier before (Liang, et al. 2013; Wei, et al. 2008), 
101 as far as we are aware, there are no studies which have investigated CaCO3 as a pH-sensitive 
102 gate-keeper to control drug release from porous nanocarriers. Moreover, therapeutic 
103 outcomes with these CaCO3-based drug delivery systems have been rarely verified in in vivo 
104 animal experiments (Liu, et al. 2017, Zhao, et al. 2018). In the present study, the developed 
105 nanovectors exhibited pH controlled drug release, a good in vitro therapeutic effect and 
106 minimal in vivo toxicity in healthy tissues after systemic administration. Furthermore, the 
107 nanovectors achieved an excellent therapeutic effect in vivo after intratumoral injection.
108
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109 2. Materials and Methods
110 2.1. Materials
111 Triethylene glycol (TEG), iron(III) acetylacetonate (Fe(acac)3), Igepal Co-520 (IGE), 
112 calcium chloride (CaCl2), sodium carbonate (Na2CO3), (3-Aminopropyl)triethoxysilane 
113 (APTES), trimethylamine (TEA), fetal bovine serum (FBS), Tween® 20 and L-glutamine 
114 were purchased from Sigma-Aldrich. Doxorubicin (DOX) was purchased from Euroasias. 
115 Cyclohexane (CH) and tetramethoxysilane (TMOS) were obtained from Merck Millipore and 
116 Alfa Aesar, respectively. Dimethyl sulfoxide was purchased from J.T. Baker. 2 kDa PEG-
117 silanes (mPEG & NH2) and 0.5 kDa mPEG-silane were purchased from Huateng Pharma and 
118 Fluorochem, respectively. Cyanide7.5 NHS ester (Cy7.5) and CellTiter-Glo were purchased 
119 from Lumiprobe and Promega, respectively. Dulbecco’s Modified Eagle Medium (DMEM) 
120 and RPMI1640 were obtained from Biowest and penicillin/streptomycin (P/S) was purchased 
121 from Hyclone. Alexa Fluor546, CellMask Deep Red, and Hoechst stain were purchased from 
122 Thermo Scientific. Silicon wafers (p+-type, resistivity 0.007-0.02 Ωcm) were received from 
123 Okmetic Oyj.
124 2.2. Synthesis of DPEG-DOX-CaFe-TOPSi
125 PSi was prepared by electrochemical pulsed etching (30 mA/cm2 for 2200 ms and 120 
126 mA/cm2 for 350 ms, total etching time 40 min) in a 1:1 mixture of hydrofluoric acid and 
127 ethanol followed by milling and centrifugation to obtain nanoparticles (NPs). The PSi NP 
128 surface was oxidized thermally and chemically according to the previous protocol for the 
129 preparation of oxidized PSi (TOPSi) (Näkki, et al. 2015). SPIONs were deposited on the 
130 surface of TOPSi nanoparticles with Fe(acac)3. Briefly, TOPSi and Fe(acac)3 (1:1 ratio) were 
131 dispersed in TEG, heated at 275 °C for 30 min, cooled down to room temperature (RT) and 
132 washed with ethanol (EtOH) to obtain SPION decorated TOPSi (Fe-TOPSi). Fe-TOPSi NPs 
133 (30 mg) were immersed in DOX (30 mg/ml in 1:1 v/v EtOH:H2O, 0.5 ml) solution to load the 
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134 drug into the pores (DOX-Fe-TOPSi). DOX-Fe-TOPSi were coated with a pH-sensitive 
135 CaCO3 layer by a microemulsion method. Briefly, DOX-Fe-TOPSi nanoparticles in the DOX 
136 loading (0.5 ml) solution were dispersed in CH:IGE mixture (volumes of 5 and 1.5 ml, 
137 respectively) with the aid of ultrasound. CaCl2 (200 µl (H2O), 0.5 M) was mixed with a 
138 similar CH:IGE mixture. The solutions of DOX-Fe-TOPSi and CaCl2 were mixed with 
139 sonication and stirred for 5 h at RT to obtain a microemulsion. Na2CO3 (200 µl (H2O), 0.5 M) 
140 was added into a similar CH:IGE mixture, subsequently mixed by sonication with the 
141 microemulsion, and stirred overnight at RT to obtain DOX-CaFe-TOPSi nanoparticles which 
142 still remained in the solution.
143 30 µl APTES and 30 µl TMOS were mixed with CH (2 ml), added to DOX-CaFe-
144 TOPSi particle solution and reacted for 5 h at RT before washing with EtOH. The previously 
145 described Dual PEGylation (Näkki, et al. 2015) was performed at lower temperatures (max 
146 70 °C) to ensure the integrity of DOX. The final particles were denoted as DPEG-DOX-
147 CaFe-TOPSi. A similar production protocol without DOX was utilized to manufacture 
148 unloaded DPEG-CaFe-TOPSi. Particles with a reactive group for dye labelling were 
149 manufactured with a similar protocol without DOX by including an extra PEGylation step 
150 before the final Dual PEGylation; The CaFe-TOPSi particles were PEGylated in toluene with 
151 NH2-PEG-silane at 70 °C overnight before Dual PEGylation to manufacture TPEG-CaFe-
152 TOPSi. 
153 2.3. Characterization
154 Fourier-transform infrared spectroscopy (FTIR, Thermo Nicolet 8700) was utilized to 
155 monitor the chemical changes after modifications by measuring total transmittance. 
156 Nanoparticle size and morphology were imaged with transmission electron microscopy 
157 (TEM, Jeol JEM 2100F) after drying a droplet of NP suspension onto a copper grid and 
158 imaging with 200 kV. The iron and CaCO3 contents were measured with atomic absorption 
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159 spectroscopy (AAS, Jena AAS ZEEnit 700) by using 248.3 nm and 422.7 nm wavelengths 
160 for iron and calcium, respectively. Thermogravimetric analysis (TGA, TA Instruments TG 
161 Q50) was utilized to measure PEG content by ramping the temperature at 20 °C/min intervals 
162 up to 800 °C in an N2 atmosphere. Ultra-visible absorption (480 nm) (UV-Vis, PerkinElmer 
163 Victor 3) was used for analyzing the amount of DOX released. Pore properties were 
164 measured from dry particles with N2 sorption (Micromeritics TriStar II 3020) at -196 °C. 
165 Specific surface areas were calculated using the Brunauer–Emmet–Teller (BET) method, and 
166 a single point method (p/p0 = 0.95) was used to obtain the pore volumes. Average pore sizes 
167 were calculated from the desorption branch using the Barrett–Joyner–Halenda (BJH) theory. 
168 X-ray powder diffraction (XRPD) (Bruker D8 Discover) was utilized to measure SPION and 
169 CaCO3 crystalline size with the Scherrer equation after full profile fitting. Magnetization was 
170 studied with a vibrating sample magnetometer (VSM, Physical Property Measurement 
171 System Dynacool, Quantum Design) equipped with a 9 T magnet. Magnetic relaxation was 
172 evaluated with a 9.4T vertical magnet (Oxford Instruments) interfaced to the Varian 
173 DirectDrive console (Agilent Technologies). The particle size and stability in PBS and 
174 plasma were measured with dynamic light scattering (Malvern, Nano ZS Zetasizer).
175 2.4. Drug release
176 DOX release from DPEG-DOX-CaFe-TOPSi NPs (~ 1,5 mg) was determined in an 
177 Eppendorf tube at pH 5, 6.5 & 7 buffer. Nanovectors were dispersed in medium with 
178 ultrasound (~ 5 s) and rotated (24 rpm) at 37 °C. At predefined time points, the nanovectors 
179 were centrifuged, the medium was collected for analysis and it was replaced with fresh 
180 buffer. All samples were analyzed with UV-Vis.
181 2.5. In vitro cell experiments
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182 The therapeutic effect was evaluated with three cancer cell lines; CT26 colon, 4T1 
183 breast and A549 lung cancer. The cells were cultured in DMEM (A549) or RPMI1640 (CT26 
184 & 4T1) supplemented with 10% FBS, 1% P/S and 1% L-glutamine. Cells were plated onto a 
185 96-well plate (15 000/cm3) and incubated with DOX, DPEG-DOX-CaFe-TOPSi or DPEG-
186 CaFe-TOPSi for 24 h. The cells were washed twice with PBS and fresh medium was 
187 replaced. The cell viability was measured with CellTiter-Glo assay after an additional 24h 
188 incubation based on the manufacturer’s instructions. Untreated cells and cells incubated with 
189 10% Tween® 20 were used as controls. The results are normalized to untreated cells (100%) 
190 and to Tween® 20 treated cells (0%).
191 The cell internalization of TPEG-CaFe-TOPSi nanoparticles was evaluated with 
192 RAW 264.7 cells cultured in DMEM supplemented with 10% FBS, 1% P/S and 1% L-
193 glutamine. The DOX amount in the cell cytoplasm after incubation with DPEG-DOX-CaFe-
194 TOPSi nanoparticles was examined in CT26 cells. Cells were plated in Ibidi 8-well plate 
195 (50 000/cm2) and incubated with Alexa Fluor546-labelled TPEG-CaFe-TOPSi (RAW 264.7) 
196 or DPEG-DOX-CaFe-TOPSi (CT26) for 4 and 24 h. The cell membranes were stained with 
197 CellMask (1 µg/ml, 7 min) and nuclei with Hoechst (1 µg/ml, 7 min) staining before imaging 
198 with confocal microscope (Zeiss, LMS700). 
199 2.6. In vivo biodistribution
200 In vivo biodistribution and safety evaluation studies were performed under the 
201 authority of project and personal licences granted by the UK Home Office and the UKCCCR 
202 Guidelines (1998). Male NOD SCID gamma (NSG) mice (~20 g) aged 4-6 weeks were 
203 obtained from Charles River (UK).
204 TPEG-CaFe-TOPSi were incubated with Cy7.5 dye (59 µM) and TEA (0.2 M) in 
205 DMSO (1 ml) overnight at RT under constant shaking. The excess dye was washed away 
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206 with EtOH and the particles were re-constituted in PBS. Male NSG mice were intravenously 
207 (i.v.) injected (tail vein) with Cy7.5-TPEG-CaFe-TOPSi (2.5 mg, with average particle size 
208 of ~250 nm) or Cy7.5-TOPSi (1 mg, with average particle size of ~250 nm) with matched 
209 fluorescent intensity. The mice were sacrificed at 4 h post injection (p.i.), and organs were 
210 collected and imaged with IVIS Lumina III in vivo imaging system (PerkinElmer). Free 
211 Cy7.5 dye dispersed in PBS (29 µM, 200 µl) was i.v. injected into male NSG mouse, 
212 sacrificed 4 h p.i. and organs imaged with IVIS. Biodistribution values are presented as % 
213 dose in each organ as compared to the total detected intensity.
214 2.7. In vivo safety evaluation with orthotopic cancer
215 A549 lung cancer models were established by i.v. injection of luciferase expressing 
216 A549-luc cancer cells (0.5 × 106) into male NSG mice. The cancer growth was evaluated 
217 after subcutaneous injection of luciferin (150 mg/kg) through bioluminescence imaging (BLI) 
218 with IVIS starting from day 7 post cancer cell inoculation. Based on the BLI signals, the mice 
219 were divided into four groups (Control, DOX, DPEG-CaFe-TOPSi or DPEG-DOX-CaFe-
220 TOPSi, n = 7) to match signal mean and S.D. between the groups as closely as possible. Each 
221 group received weekly i.v. injection of either PBS, free DOX (5 mg/kg), DPEG-CaFe-TOPSi 
222 (50 mg/kg, ~250 nm, Table S1) or DOX-DPEG-CaFe-TOPSi (50 gm/kg, DOX equivalent 5 
223 mg/kg, ~250 nm) until they were sacrificed. The mice were monitored for up to 45 days 
224 unless they exhibited symptoms or displayed a 20% weight loss as compared to initial 
225 weight. At sacrifice, blood samples were collected and major organs were excised, weighed, 
226 and fixed for histopathological analysis.
227 2.8. In vivo therapy evaluation with subcutaneous cancer model
228 In vivo animal therapy experiments were approved by the Animal Experiment 
229 Administration Committee of the Fourth Military Medical University, China. CT26 cells (5 × 
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230 106 cells) were injected into female BALB/c nude mice legs subcutaneously in order to 
231 establish tumors. Tumor growth was measured with calipers and upon reaching a diameter 
232 greater than 0.2 cm, the mice were randomly divided into four groups and given a single 
233 intratumoral injection of PBS, DOX (5 mg/kg), DPEG-CaFe-TOPSi (50 mg/kg, 250 nm) or 
234 DPEG-DOX-CaFe-TOPSi (50 mg/kg, DOX equivalent of 5 mg/kg, 250 nm). All animals 
235 were monitored for activity, physical condition, body weight, and tumor growth until 
236 sacrificed at day 10 post treatment. The tumor volume was calculated with the formula V= ½ 
237 (width2·length). The excised tumors were weighed and imaged, furthermore the major organs 
238 were collected for further analysis.
239 2.9. Histology and blood biochemistry
240 Heart, A549 lung, liver, spleen and kidney specimens from the in vivo safety 
241 experiment were fixed and stained with hematoxylin and eosin (H&E). Similarly, the major 
242 organs (heart, lung, liver, spleen and kidney as well as the tumor) from in vivo therapy 
243 experiment were prepared and H&E stained. Furthermore, the tumors were stained with the 
244 TUNEL assay to determine the numbers of apoptotic cells in the tumor sections. H&E stained 
245 slices were imaged with light microscopy to evaluate the toxicity of each treatment. Serum 
246 was extracted from the drained blood by centrifugation and analyzed for alanine 
247 aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), 
248 blood urea nitrogen (BUN) and creatine kinase (CK) enzymes.
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249 3. Results and discussion
250 The morphology of TOPSi, Fe-TOPSi and CaFe-TOPSi nanoparticles was studied 
251 with TEM imaging; the particles had irregular elongated or roundish shapes. Furthermore, 
252 TEM revealed 10 nm sized SPIONs on the surface of Fe-TOPSi, and a 30 nm layer of CaCO3 
253 was observed on the surface of CaFe-TOPSi which was not present in TOPSi (Figure 1A-C). 
254 The nanoparticles were then studied with XRPD (Figure S1) from which a crystallite size of 
255 Fe3O4 of 3.5 ± 0.1 nm as calculated with the Scherrer equation after full profile fitting. The 
256 obtained crystallite size of CaCO3 (33.5 ± 1.1 nm) matched well with the thickness evaluated 
257 by TEM. Furthermore, the mean amount of Fe3O4 was 9 wt% and the CaCO3 amount was 22 
258 wt% as evaluated with AAS.
259 The CaFe-TOPSi nanoparticles displayed magnetic behavior in the presence of a 
260 permanent magnet (Figure S2) and magnetic performance was further validated with VSM 
261 and MRI. The superparamagnetic saturation magnetization from Fe-TOPSi was 100.7 
262 emu/gFe (Figure 1D), and the T2-relaxivity of CaFe-TOPSi was 520 ± 20 ml/(mg·s) 
263 compared to the total particle mass (Table 1). The DPEGylation decreased the T2-relaxivity 
264 to 186 ± 5 ml/(mg·s) on DPEG-CaFe-TOPSi due to impaired water flow near to the particle 
265 surface (Nissinen, et al. 2016). The obtained values highlight the good magnetic performance 
266 for MRI diagnostics and as far as we are aware, this magnetization value is one the highest 
267 ever reported for magnetic PSi (Kinsella, et al. 2011; Xia, et al. 2017).
268 Tumor tissues have a lower pH (6.5-7) in comparison to normal tissue (Gallagher, et 
269 al. 2008; Sun, et al. 2016); this is anticipated to trigger the pH-sensitive drug release from 
270 DPEG-DOX-CaFe-TOPSi. The CaCO3 is practically insoluble at neutral pH and thus blocks 
271 the pores in a neutral environment like the bloodstream and therefore protects the drug from 
272 premature release in blood and minimizes the absorption of the drug by healthy tissues. The 
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273 CaCO3 dissolves better in acidic conditions, and this enhances the drug release in the tumor 
274 environment (Liu, et al. 2017). The pore blocking by CaCO3 was studied with N2 sorption; 
275 this revealed the clear differences between CaFe-TOPSi and TOPSi (Figure 1E). The 
276 hysteresis between adsorption and desorption isotherms is related to mesoporosity and non-
277 porous materials do not display this phenomenon whereas the isotherm height is related to the 
278 total pore volume. The surface area and pore volume, calculated with BET and single point 
279 approximation (p/p0 = 0.95) respectively, decreased by 90% and 86% due to the CaCO3 
280 coating, respectively (Table 1). The obtained large pore size in CaFe-TOPSi and DPEG-
281 CaFe-TOPSi is anticipated to be due to the inter-particle cavities instead of the pores within 
282 the sample, since the starting material (TOPSi) had a narrow pore size distribution between 5 
283 and 20 nm whereas there was a distribution of the CaFe-TOPSi pores, ranging up to 80 nm 
284 (Figure S3). The lack of the pores with diameters below 20 nm, which are a normal 
285 characteristic of a PSi material, emphasizes that CaCO3 exerts a pore blocking effect. FTIR 
286 showed characteristic peaks of CaCO3 (Figure S4) indicating successful coating, and the total 
287 PEG content was 15.2 ± 0.8 wt% based on TGA (Figure S5).
288 Since the biological stability of the nanoparticles is a critical factor of a good drug 
289 carrier, the size changes of DPEG-CaFe-TOPSi in PBS and plasma were evaluated as a 
290 function of the incubation time (Figure 2A&B and Figure S6). The negligible changes in 
291 size in both physiological conditions are evidence of the improved and long-term colloidal 
292 stability after DPEGylation. The pH sensitive drug release from DPEG-DOX-CaFe-TOPSi 
293 was evaluated by measuring DOX release kinetics in vitro at three different pH levels (pH 5, 
294 6.5 & 7). The drug release was in good agreement with our hypothesis since the DOX release 
295 was clearly inhibited at pH 7, it was moderate at pH 6.5 and the release was extensive at pH 5 
296 (Figure 2C). The difference in drug release was proposed to be mainly due to CaCO3 since 
297 free DOX was seen to rapidly dissolve at pH 5 and 7 buffers (Figure S7). The total amount 
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298 of DOX in DPEG-DOX-CaFe-TOPSi, evaluated from the released drug amount with UV-
299 VIS, was 10.3 ± 1.4 wt% (Figure S8). Furthermore, TGA results (Figure S5) indicate that 
300 the DOX content was 9.2 ± 1.1 wt%, correlating well with the value obtained from the UV-
301 VIS analysis.
302 Table 1.The porous and magnetic properties of porous silicon
Sample Surface areaa 
(m2/g)
Pore volumeb 
(cm3/g)
Pore size 
(nm)c
T2-relaxivityd
(ml/mg·s)
TOPSi 190 ± 20 0.50 ± 0.04 9.9 ± 0.2 -
CaFe-TOPSi 20 ± 2 0.07 ± 0.01 43 ± 6* 520 ± 20
DPEG-CaFe-TOPSi 6 ± 2 0.03 ± 0.02 42 ± 6* 186 ± 5
303 a Surface area of the samples calculated according to BET theory from N2 sorption isotherms (mean ± S.D., n = 
304 3). 
305 b Pore volume of the samples calculated with single-point approximation (p/p0 = 0.95) from N2 sorption 
306 isotherms (mean ± S.D., n = 3).
307 c Pore sizes calculated with the BJH theory from N2 sorption isotherms (mean ± S.D., n = 3). 
308 d T2-relaxivity (with least squares fitting error).
309 * The value corresponds to the inter-particle cavities rather than the real pore size
310
311 The in vitro therapeutic effect was studied with CT26, 4T1 and A549 cell lines in 
312 order to gain a more comprehensive understanding of the feasibility of using DPEG-DOX-
313 CaFe-TOPSi for cancer therapy. While DPEG-CaFe-TOPSi displayed excellent 
314 biocompatibility (Figure S10-12), the DPEG-DOX-CaFe-TOPSi revealed evidence of dose-
315 dependent cytotoxicity similar to free DOX (Figure 2 D-F). In general, the DPEG-DOX-
316 CaFe-TOPSi exhibited a slight reduction in cytotoxicity as compared to free DOX. This 
317 phenomenon is frequently observed with nanoparticles (Liu, et al. 2016; Zhang, et al. 2014) 
318 and can be related to the controlled release of the drug molecules. Moreover, based on the 
319 confocal microscopy examination, the PEG layer seemed to hinder and delay the cell uptake 
320 of the particles (Figure S13). This affected the release and overall content of DOX in the 
321 cells (Figure S14) whereas free DOX could enter the cells via passive diffusion and interact 
322 more rapidly with the cells. This may account for the differences detected in the cytotoxicity 
323 of these particles. Furthermore, the cell lines responded differently to treatment with DOX 
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324 and DPEG-DOX-CaFe-TOPSi; the 4T1 cell line was the most sensitive, the CT26 cell line 
325 displayed the lowest therapeutic response (Figure S15 & S16). 
326 The in vivo biodistribution in healthy male NSG mice was evaluated 4 h after 
327 intravenous administration of shielded Cy7.5-dye labelled TPEG-CaFe-TOPSi nanoparticles 
328 and compared with bare Cy7.5-TOPSi nanoparticles. The TPEG-CaFe-TOPSi particles 
329 accumulated significantly less in liver, lungs and kidneys, and more in spleen as compared 
330 with the non-PEGylated counterpart (Figure 3A). The high lung uptake of TOPSi can be 
331 related to its poor stability in biological fluids (Figure 2A-B). The rapid aggregation of the 
332 TOPSi nanoparticles leads to their entrapment in the small capillaries of the lungs while 
333 TPEG-CaFe-TOPSi nanoparticles were able to maintain their original size and become 
334 distributed in other tissues. TOPSi nanoparticles accumulated mainly in liver which is usually 
335 the main organ which takes up and removes nanoparticles from the bloodstream (Rytkönen, 
336 et al. 2012; Wang, et al. 2016). The PEGylated nanoparticles however accumulated mostly in 
337 the spleen; this can be attributed to the shielding effect of PEG and the changed ζ-potential 
338 (Table S2). PEGylation affects the opsonized protein corona not only by decreasing the total 
339 amount of protein being absorbed but also by altering the nature of these proteins, leading to 
340 a “stealth” effect, an increased blood half-time and a different biofate (Nissinen, et al. 2016). 
341 Furthermore, long blood residence times together with high spleen accumulation have been 
342 reported (He, et al. 2011; Kramer, et al. 2017) indicating that there could be a possible 
343 correlation between these two factors. The DPEGylation significantly decreased the signal 
344 from the kidneys. This can be related to the small Cy7.5 molecule being excreted out of the 
345 bloodstream through the kidneys after being detached from the nanoparticles after their 
346 degradation. The DPEGylation slows down the particle degradation as compared with the 
347 non-modified particles (Näkki, et al. 2015) affecting the amount of free Cy7.5 in the blood. 
348 Moreover, the free Cy7.5 after i.v. administration is mainly accumulated in the kidneys 
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349 corroborating this hypothesis (Figure S17). Overall, the biodistribution data suggest that 
350 DPEGylation had improved the pharmacokinetics of the particles in the blood.
351 The safety of the developed nanovectors was evaluated in male NSG mice which had 
352 been inoculated with lung tumor and luciferase-expressing A549 cells. The weight and 
353 behavior of the mice were monitored starting from the day of tumor inoculation until day 45 
354 post-inoculation when the experiment was terminated. The tumor growth was monitored by 
355 whole body BLI imaging after administration of luciferin. Each group received weekly 
356 treatment with either PBS (Control), DOX, DPEG-CaFe-TOPSi or DPEG-DOX-CaFe-TOPSi 
357 starting from day 7 post-tumor cell inoculation. The DOX dose in the drug-treated groups 
358 was 5 mg·kg-1/treatment with the corresponding particle amount being 50 mg·kg-1/treatment. 
359 The mice in the DOX group started to lose weight soon after receiving the first treatment due 
360 to the toxicity of the cytostatic drug (Figure 3B) and they had to be sacrificed on days 17-18 
361 after losing more than 20% of their body weight as compared to the starting situation. 
362 Furthermore, the mice in the DOX group displayed abnormal behavior with an untidy 
363 appearance and they appeared to have small eyes.
364 On the contrary, no weight loss or other symptoms were observed in the other groups 
365 including the control group. At the end of the experiment, blood was sampled and major 
366 organs i.e. heart, lung, liver, spleen and kidney were excised. It was found that many organs 
367 in the DOX group were significantly smaller than the corresponding organs in the other 
368 groups (Figure S18). The DOX toxicity was unexpected since the 5 mg·kg-1 dose (Wang, et 
369 al. 2016) is commonly used and even doses as high as 18 mg·kg-1 have been administered to 
370 mice without any significant toxicity (Cai, et al. 2015). Furthermore, the maximum tolerance 
371 level for DOX has been reported to be 8 mg·kg-1 whereas the loading to nanoparticles can 
372 elevate this up to 40 mg·kg-1 (Yang, et al. 2016). The reduced drug tolerance may be due to 
373 the nature of NSG mice which are one of the most immunodeficient mouse strains (Shultz, et 
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374 al. 2007). Surprisingly, the tumors in DOX and DPEG-DOX-CaFe-TOPSi groups did not 
375 show any regression, in fact even the opposite effect was encountered in the DOX group 
376 where the tumors were significantly larger than in the other groups (day 17) (Figure 3C). We 
377 have been unable to find any other reports of a similar effect after administration of DOX. 
378 We hypothesize that it is attributable to the severe toxicity of DOX weakening the animals 
379 such that they were not able resist the tumor growth as effectively as their counterparts in the 
380 other groups. 
381 Histopathological changes and several biomarkers were examined to determine in 
382 detail the toxicity in the vital organs. Blood urea nitrogen (BUN) levels were found to be 
383 slightly but not significantly elevated in DPEG-CaFe-TOPSi and DPEG-DOX-CaFe-TOPSi 
384 groups indicating no nephrotoxicity had occurred in these groups (Figure 3D). On other hand, the 
385 liver enzyme levels (ALT & AST) were significantly elevated in the DOX group as compared to 
386 the control group, i.e. evidence of hepatotoxicity (Figure 3E). No significant increases in liver 
387 enzymes were found in DPEG-CaFe-TOPSi and DPEG-DOX-CaFe-TOPSi groups as compared 
388 to the control group. Although DOX is known to possess cardiotoxic properties (Takemura and 
389 Fujiwara 2007), there was no major elevation of the creatine kinase (CK) levels in any of the 
390 treatment groups (Figure 3F). Images of representative H&E stained tissues from vital organs are 
391 shown in Figure 3G. Myocardial pathology commonly associated with doxorubicin treatment 
392 such as myofibrillar loss and cytoplasmic vacuolisation (Chatterjee, et al. 2009) was not observed 
393 in the DOX group which could be due to the early stage of the treatment. It should be noted that 
394 the DOX group was sacrificed earlier (days 17-18) than the other groups (day 45) due to the 
395 significant side effects and mice in this group received only two injections while the other groups 
396 were treated six times. Liver damage was evident in the DOX group i.e. there was a loss of blood 
397 sinusoid and the development of fatty droplets (Figure 3G). Clear changes in spleen tissue 
398 histology were also observed with fewer white pulp areas (the blue staining represents 
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399 lymphocytes) seen in the cross-sections. In contrast, mice receiving DPEG-CaFe-TOPSi or 
400 DPEG-DOX-CaFe-TOPSi did not differ from the control group in the histology of the examined 
401 vital organs. Overall, the serum biochemistry and histopathological analyses indicate that free 
402 DOX evoked toxicity in the mice while DPEG-CaFe-TOPSi and DPEG-DOX-CaFe-TOPSi were 
403 safe at these doses. As a summary, the loading of DOX inside of the nanoparticle was able to 
404 nullify the toxic effects evoked by free DOX, a phenomenon attributed to the pH-controlled drug 
405 release.
406 To further evaluate the possibility that the nanovectors could be utilized in MRI-based 
407 monitoring, the liver and lungs from the control, DPEG-CaFe-TOPSi and DPEG-DOX-CaFe-
408 TOPSi groups were imaged. R2 relaxivity was determined in order to detect possible differences 
409 since iron is known to increase R2 values. The liver and lung r2 values were significantly elevated 
410 in DPEG-CaFe-TOPSi and slightly increased in DPEG-DOX-CaFe-TOPSi group as compared to 
411 the control group, indicating the presence of nanoparticles (Figure S19 and Table S3). Therefore, 
412 after their intravenous administration, these particles display properties which can be utilized in 
413 MRI diagnostics (Nissinen, et al. 2016).
414 The in vivo antitumor efficacy was evaluated with subcutaneous CT26 tumor bearing 
415 female BALB/c nude mice which had received a single intratumoral injection. The treatment 
416 was conducted when the tumors reached 0.2 cm in diameter (day 7 after tumor inoculation). 
417 The body weights of the mice were evaluated every second day until the mice were sacrificed 
418 at day 10 post-injection (Figure 4A). The mice in the control, DPEG-CaFe-TOPSi or DPEG-
419 DOX-CaFe-TOPSi groups did not show any weight differences but the mice in the DOX 
420 group started to lose weight 4 days p.i, an effect associated with DOX’s toxicity. 
421 Furthermore, one mouse in the DOX group died during the monitoring period (at day 8 p.i.) 
422 further highlighting the adverse effect of the cytostatic drug treatment. The tumor volumes 
423 increased steadily in the control and DPEG-CaFe-TOPSi groups throughout the whole 
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424 experiment period (Figure 4B). However, smaller tumor volumes were observed 6 day p.i. in 
425 DOX and DPEG-DOX-CaFe-TOPSi groups, and at 10 day p.i. the measured tumor volumes 
426 in DOX and DPEG-DOX-CaFe-TOPSi group were significantly smaller than in the other 
427 groups (Figure 4B).
428 The tumors were weighed at the end of the experiment and showed similar results 
429 (Figure 4C); the tumors in the DOX and DPEG-DOX-CaFe-TOPSi groups were 
430 significantly lighter and smaller than those in the control group while no significant 
431 difference was detected in the group receiving DPEG-CaFe-TOPSi (Figure 4D). Comparable 
432 and significant tumor size reductions were observed in the DPEG-DOX-CaFe-TOPSi (77%) 
433 and DOX (81%) treated tumors, evidence of an excellent therapeutic response. Furthermore, 
434 the level of apoptosis was evaluated in tumors with the TUNEL assay. In agreement with our 
435 in vivo antitumor efficacy results, the tumors dissected from DOX and DPEG-DOX-CaFe-
436 TOPSi groups exhibited similar levels of TUNEL-positive cells indicative of apoptosis 
437 (brown colour) (Han, et al. 2017); their numbers were clearly higher than the corresponding 
438 values in the control and DPEG-CaFe-TOPSi groups (Figure 4E). Furthermore, the toxicity 
439 towards vital organs was evaluated with H&E staining (Figure S20). In comparison with the 
440 control group, the DOX group showed significant lesions in liver, spleen and lung although 
441 the drug had been administered only 10 days earlier. Hepatonecrosis had occurred and there 
442 were obvious lesions in the splenic germinal center in the DOX group. Moreover, some 
443 pulmonary fibrosis could be observed in the DOX group. In contrast, the mice in the other 
444 groups did not develop any significant organ lesions, indicating that the free DOX alone 
445 causes severe toxicity while the nanoparticles and the DOX loaded nanoparticles seem to be 
446 safe. These results suggest that the nanovectors were able to retain the drug more efficiently 
447 in the tumor while free drug was escaping the tumor environment, causing toxic effects and 
448 damaging vital organs.
  
449 4. Conclusions
450 The designed magnetic pH-responsive nanovectors based on porous silicon 
451 nanoparticles exhibited good magnetic behaviour, excellent colloidal stability and pH-
452 sensitive drug release in vitro and displayed effective therapeutic efficacy. The drug loaded 
453 nanovectors did not cause any adverse side effects after systemic administration, being 
454 apparently safe over a relatively long time-scale (45 days) and were detectable with MRI ex 
455 vivo. Furthermore, the nanovectors exhibited a comparable therapeutic response in vivo as 
456 with free drug but without inducing similar unwanted effects. Therefore, these novel 
457 multifunctional PSi nanovectors are very promising candidates and may represent next 
458 generation nanomedicines for cancer therapy.
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619
620 Scheme 1. Schematic illustration of particle modification routes. Oxidized PSi (TOPSi) 
621 nanoparticles are immersed in triethylene glycol (TEG) with iron(III) acetylacetonate 
622 (Fe(acac)3) and heated to produce SPIONs on the surface of TOPSi (Fe-TOPSi). DOX is 
623 loaded in the pores of the Fe-TOPSi nanoparticles and calcium carbonate coating is 
624 conducted in cyclohexane (CH):Igepal Co-520 (IGE) solution (DOX-CaFe-TOPSi). Dual 
625 PEGylation is applied in toluene to shield the nanoparticles with PEG (DPEG-DOX-CaFe-
626 TOPSi). A similar protocol without DOX is utilized to manufacture particles for fluorescent 
627 imaging with the exception of the addition of extra PEG molecules with an amine group on 
628 the shielding step and labeling with Cy7.5 in the final step (Cy7.5-TPEG-CaFe-TOPSi).
  
629  Figure 1. TEM images of A) TOPSi B) Fe-TOPSi with 10 nm SPIONs on the surface and C) 
630 CaFe-TOPSi with visible CaCO3 layer of 30 nm. The scale bar is 100 nm. D) The saturation 
631 magnetization of Fe-TOPSi was evaluated with VSM, with a value of 100.7 emu/gFe being 
632 obtained. E) Nitrogen sorption results for TOPSi, CaFe-TOPSi and DPEG-café-TOPSi 
633 indicative of the pore blocking induced by the CaCO3-layer.
  
634 Figure 2. The colloidal stability of TOPSi and DPEG-CaFe-TOPSi in A) PBS and B) plasma 
635 reflecting the increased stability of DPEG-CaFe-TOPSi. C) DOX release from nanovectors in 
636 pH 5, 6.5 and 7 buffers showing capability of DPEG-DOX-CaFe-TOPSi for achieving pH 
637 sensitive drug release. D) CT26, E) 4T1 and F) A549 cancer cell viability after 24 hours’ 
638 incubation with DOX or DPEG-DOX-CaFe-TOPSi with equivalent DOX doses. Cell 
639 viability was evaluated from luminescence with the CellTiter Glo assay. All results are 
640 presented as mean ± S.D. (n ≥ 3). Significant differences were examined with two-way 
641 ANOVA followed by Sidak’s test (*p<0.05, ***p<0.001, ****p<0.0001).
  
642 Figure 3. A) Biodistribution of the Cy7.5 labelled TOPSi and TPEG-CaFe-TOPSi in healthy 
643 mice at 4 h post-injection presenting organ distribution scaled to the total detected intensity 
644 measured ex vivo with IVIS. B) Animal weight during i.v. treatment with PBS (Control), 
645 DOX (5 mg/kg), DPEG-CaFe-TOPSi (50 mg/kg) or DPEG-DOX-CaFe-TOPSi (50 mg/kg, 
646 DOX equivalent 5 mg/kg) in A549 lung tumor bearing mice. Tumors were inoculated at 0 d 
647 and treatments were given once a week starting at day 7 post-inoculation. The animals in the 
648 DOX group were sacrificed at 17-18 d post tumor inoculation and received two treatments 
649 while other groups were sacrificed at 45 d post tumor inoculation and received six treatments. 
650 C) The A549 lung tumor size which was evaluated from the bioluminescence signal arising 
651 from the tumor after administration of luciferin. The evaluation of blood biochemical 
652 parameters of D) kidney enzyme BUN, E) liver enzymes ALT, AST and ALP, and F) heart 
653 enzyme CK from PBS (Control), DOX, DPEG-CaFe-TOPSi and DPEG-DOX-CaFe-TOPSi 
654 treated mice. G) Histological examination of vital organs with H&E staining. Scale bar, 50 
655 µm. Results are presented as mean ± S.D. (n ≥ 3). Significant differences (compared to 
656 control group (black)) were examined with two-way ANOVA followed by Sidak’s test 
657 (*p<0.05, ***p<0.001, ****p<0.0001).
  
29
658 Figure 4. A) Body weight of CT26 bearing BALB/c mice post-injection. The mice were 
659 treated with a single intravenous injection of PBS, DOX (5 mg/kg), DPEG-CaFe-TOPSi (50 
660 mg/kg) or DPEG-DOX-CaFe-TOPSi (50 mg/kg, DOX equivalent 5 mg/kg) at day 0. B) 
661 Relative tumor growth progression during the 10 day experiment. B) The tumor volume 
662 growth progression curves for CT26 tumors during the 10 day period of the experiment. C) 
663 Tumor weights 10 d p.i. D) Tumors collected from mice at the end of the experiment (day 10) 
664 .E) TUNEL assay of tumor biopsies from all treatment groups. Images were randomly taken 
665 at 200x magnification for each specimen. Results are presented as mean ± S.D. (n = 5) except 
666 for the DOX group where one animal died on day 8 after treatment. Significant differences 
667 (compared to the control group (black)) were examined using two-way ANOVA followed by 
668 Sidak’s test (A&B) and one-way ANOVA followed by Tukey’s test (C) (**p<0.01, 
669 ****p<0.0001).
670
671
672
673
674
675
676
677
  
30
678
679
  
31
680
  
32
681
  
33
682
683
